Past News

We present compelling conceptual evidence that targeting the AnxA1/FPR2/ALX pathway may provide new therapeutic possibilities against thromboinflammatory conditions such as Sickle Cell Disease.

Shreya moved from King's College London to join the Gavins Lab at Brunel University London, where she will work on the study of inflammation resolution.

We present novel findings regarding the multifaceted role that AnxA1 plays in stroke. Such discovery could pave the way for novel and more personalized approaches to antiplatelet therapy.